stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Revenue
Fortrea Holdings Inc.'s revenue for fiscal 2025 was $2.7B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $2.7B. Over the past ten years it has ranged from $2.6B (fiscal 2020) to $3.1B (fiscal 2021); the current reading is higher than 50% of that period. Fortrea Holdings Inc. ranks 11th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.7B | 1.00% |
| FY2024 | $2.7B | (5.14%) |
| FY2023 | $2.8B | 0.19% |
| FY2022 | $2.8B | (7.21%) |
| FY2021 | $3.1B | 18.51% |
| FY2020 | $2.6B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $691.5M | 1.96% |
| Jun 2026 | $678.2M | 6.55% |
| Mar 2026 | $636.5M | (3.63%) |
| Dec 2025 | $660.5M | (5.82%) |
| 13 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| FTRE Fortrea Holdings Inc. | $2.7B |
| SRPT Sarepta Therapeutics, Inc. compare | $2.0B |
| BHVN Biohaven Ltd. compare | $995.4M |
| HRMY Harmony Biosciences Holdings, Inc. compare | $989.4M |
| VIR Vir Biotechnology, Inc. compare | $302.8M |
| ZYME Zymeworks Inc. compare | $37.1M |
| IMNM Immunome, Inc. compare | $12.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item